Frontier to PiT

Output Explorer

Every prompt in the paper, and what each model wrote back.

Return exactly ten single-sentence facts as JSON. Quality was judged pairwise; here you see the raw outputs and whether the JSON parsed.

9 of 1,000 prompts

HBB · Q3 20252025-11-05DBD · Q2 20252025-08-06VRME · Q2 20252025-08-13AVAV · Q2 20262025-12-09PCTY · Q4 20252025-08-05AMPG · Q2 20252025-08-14ABBV · Q2 20252025-07-31PHR · Q1 20272026-05-27MGNI · Q3 20252025-11-05

Nearby prompts. All 1,000 Earnings calls prompts

PromptABBV· Q2 2025 · call on2025-07-31· transcript 59,119 characters
Analyze the following earnings call transcript and extract the 10 most investor-relevant facts.

Each fact must:
- Be drawn only from the transcript (do not use any outside information).
- Be a single sentence capturing a specific, quantified insight relevant to investors.
- Avoid regurgitating the transcript verbatim; instead, synthesize and distill the information into investor-relevant facts.

Return only a JSON object with this exact structure (no markdown fences, no commentary):
{"facts": ["<fact 1>", "<fact 2>", ..., "<fact 10>"]}

The list must contain exactly 10 facts.

Transcript:
<transcript>
transcript redacted — the source calls are not publicly licensed
</transcript>
System prompt · identical for every setup
You are a financial analyst. You extract the most investor-relevant facts from earnings call transcripts to help investors anticipate the stock's reaction to the call.
Reference

No reference summary is published. Quality was judged pairwise by a separate model and is reported in aggregate on the main page.

Models
4 of 4 columns · click a model to add or remove it

Ours

10 facts · valid JSON
  1. AbbVie reported Q2 adjusted earnings per share of $2.97, beating its guidance midpoint by $0.11 despite a $0.42 acquired IPR&D expense hit.
  2. The company generated $15.4 billion in total net revenues for the quarter, exceeding internal expectations by more than $400 million.
  3. Skyzir global sales reached $4.4 billion with 61.8% year-over-year growth, driving the ex-Humira platform which is now on pace to generate over $25 billion in combined annual sales with Rinvoq.
  4. AbbVie raised its full-year revenue guidance to $60.5 billion, representing a total increase of $1.5 billion since the start of the year, and lifted its EPS guidance by $0.21 to a range of $11.88 to $12.08.
  5. Phase III trial results for Rinvoq in alopecia areata showed that 54% of patients on the 30mg dose achieved at least 80% scalp hair coverage, significantly outperforming placebo rates.
  6. Headline data from the TEMPLE migraine study demonstrated that Qulpta had a discontinuation rate due to adverse events of only 12% compared to 30% for Topamacraatchamatchaatchama.
  7. AbbVie closed a transaction with Uberbra for a long-acting obesity treatment and announced the planned acquisition of Capstan Therapeutics to develop in vivo CAR-T platforms for immunology.
  8. Humira global sales declined 58.2% operationally to just over $1.1 billion as exclusionary formularies continue to restrict U.S. access throughout the second half of the year.
  9. Adjusted gross margin remained robust at 84.4% of sales, while adjusted operating margin was 44.3% before adjusting for a 5.3% unfavorable impact from IPR&D amortization.
  10. AbbVie executed more than 30 business development transactions since the beginning of last year to augment its pipeline across immunology, oncology, and neuroscience.
1,833 characters472 tokens

Aux 2015

10 facts · valid JSON
  1. Skyrizi continues to demonstrate impressive growth
  2. Skyrizi continues to grow and achieve total psoriatic disease market leadership
  3. Rinvoq continues to demonstrate outstanding growth
  4. Rinvoq continues to be on pace to deliver more than $25 billion in combined sales
  5. HUMIRA biosimilar competition
  6. Skyrizi and Rinvoq together capture 1 out of every 2 in-play Crohn's disease patients
  7. Skyrizi and Rinvoq together capture 1 out of every 3 in-play UC patients
  8. Skyrizi and Rinvoq together are capturing 1 out of every 2 in-play psoriatic disease patients
  9. Skyrizi and Rinvoq together are capturing 1 out of every 3 in-play IBD patients
  10. Skyrizi and Rinvoq together are capturing 1 out of every 2 in-play Crohn's disease patients
1,640 charactersfirst of 2 attempts431 tokens

PiT-FT 2015

Invalid JSONshown as written
<|assistant|>
<|assistant|>
<|assistant|>

The same 14-character fragment repeats 292 times until the token limit. Showing the first three.

4,099 charactersfirst of 2 attempts2,048 tokens

ChronoGPT 2015

Invalid JSONshown as written

### Final Answer:
26 charactersfirst of 2 attempts11 tokens